Alteogen signs $365 million Hybrozyme licensing deal for subcutaneous biologic

The agreement gives an undisclosed global pharmaceutical company worldwide rights to use Alteogen’s ALT-B4 technology to develop and commercialise a subcutaneous formulation of an existing biologic.

Alteogen has signed an exclusive global licensing agreement with an undisclosed pharmaceutical company for ALT-B4 (berahyaluronidase alfa), based on its Hybrozyme platform, in a transaction worth up to $365 million including contingent milestone payments.

The agreement extends the commercial reach of Alteogen’s drug-delivery technology, which enables biologic medicines normally administered intravenously to be reformulated for subcutaneous administration.

Field	Content
Alert Type	Deal
Companies	Alteogen; undisclosed global pharmaceutical company
Deal Type	Exclusive licensing agreement
Asset or Company	ALT-B4 (berahyaluronidase alfa), based on Alteogen’s Hybrozyme platform, for development of a subcutaneous formulation of an undisclosed biologic
Technology or Modality	Recombinant human hyaluronidase drug-delivery technology
Deal Value	Up to $365 million, comprising an upfront payment and potential development, regulatory and commercial milestone payments. The maximum value is contingent and should not be treated as guaranteed consideration.
Development Stage	The partner’s underlying biologic is already marketed, while the ALT-B4-enabled subcutaneous formulation remains in development.
Geography	Worldwide
What Happened	On 6 August 2026, Alteogen announced an exclusive licensing agreement granting an undisclosed global pharmaceutical company worldwide rights to use ALT-B4 to develop and commercialise a subcutaneous formulation of an existing biologic product. The agreement has a potential value of up to $365 million, including contingent development, regulatory and commercial milestones. The partner and underlying biologic have not been disclosed because of competitive considerations. (Yahoo Finance)
Why It Matters	The agreement adds another pharmaceutical partner for Alteogen’s Hybrozyme platform and extends the potential application of ALT-B4 to an additional commercial biologic. Converting intravenous biologics to subcutaneous administration can reduce administration time and change treatment delivery, although the clinical and commercial significance of this programme cannot yet be assessed fully because the partner and product remain undisclosed. (Yahoo Finance)
Supporting Context	ALT-B4 temporarily breaks down hyaluronic acid beneath the skin, enabling larger-volume subcutaneous administration of biologics. Alteogen has previously licensed Hybrozyme technology to pharmaceutical companies including MSD, AstraZeneca, GSK, Daiichi Sankyo, Biogen, Sandoz, Intas and Sanofi. (알테오젠 ALTEOGEN)
Strategic Rationale	The partner gains access to technology that could enable an existing intravenous biologic to be developed as a subcutaneous formulation, while Alteogen expands the number of programmes using ALT-B4 and retains potential milestone-based economics from successful development and commercialisation.
Potential Impact	If successfully developed and approved, the programme could provide a more convenient administration option for the undisclosed biologic and further validate Hybrozyme as a platform for converting established intravenous therapies to subcutaneous formulations. The impact will depend on the identity of the product, clinical development and regulatory approval.
Key Takeaway	The $365 million agreement extends Alteogen’s Hybrozyme licensing network by adding another global programme aimed at converting an established biologic to subcutaneous administration.
What to Watch	Disclosure of the pharmaceutical partner and underlying biologic, initiation of development and subsequent clinical and regulatory milestones for the ALT-B4-enabled formulation.
Primary Source	Alteogen corporate disclosure, 6 August 2026
Relevant Date	6 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com